Akari Therapeutics (AKTX) Other Non Operating Income (2014 - 2026)

Akari Therapeutics has disclosed Other Non Operating Income across 9 years of filings, most recently posting $64000.0 for Q1 2026.

• Other Non Operating Income for Q1 2026 came in at $64000.0, up 151.2% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.1 million (up 96.13% YoY), and the FY2025 annual result was -$230000.0, down 3933.33% from the prior year.
• Other Non Operating Income came in at $64000.0 for Q1 2026 at Akari Therapeutics, up from -$130000.0 in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $208000.0 in Q4 2023 to a low of -$28.0 million in Q4 2024.
• The 4-year median for Other Non Operating Income is -$11000.0 (2023), against an average of -$2.2 million.
• Peak annual rise in Other Non Operating Income reached 409.09% in 2024, while the deepest fall reached 13564.9% in 2024.
• Akari Therapeutics' Other Non Operating Income stood at $208000.0 in 2023, then plunged by 13564.9% to -$28.0 million in 2024, then surged by 99.54% to -$130000.0 in 2025, then jumped by 149.23% to $64000.0 in 2026.
• The last three Other Non Operating Income figures came in at $64000.0 (Q1 2026), -$130000.0 (Q4 2025), and -$967000.0 (Q3 2025), per Business Quant data.